[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100420378":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":17,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":17,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":17,"enrollmentInfo":62,"targetDuration":17,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":17,"overallStatus":35,"whyStopped":17,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cilostazol","EXPERIMENTAL","Cilostazol 100mg BID",[13],"Drug: Cilostazol",{"label":15,"type":16,"description":17,"interventionNames":17},"No intervention","NO_INTERVENTION",null,[19],{"type":20,"name":9,"description":11,"armGroupLabels":21,"otherNames":17},"DRUG",[9],[23],{"name":24,"affiliation":5,"role":25},"Michelle P Lin, MD, MPH","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":17,"email":31},"Meredith McDonald","CONTACT","904-953-4200","mcdonald.meredith@mayo.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Mayo Clinic Florida","RECRUITING","Jacksonville","Florida","32224","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-81.65565,30.33218,{"lat":45,"lon":44},[48],{"name":28,"role":29,"phone":30,"phoneExt":17,"email":31},{"type":25,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Michelle P. Lin","Principal Investigator","100420378","phase-1-retina-is-a-marker-for-cerebrovascular-heath-100420378",false,"NCT04753970","Retina is a Marker for Cerebrovascular Heath","Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression","Inclusion Criteria:\n\n* Age ≥18 yo.\n* Diagnosis of CADASIL, sporadic WMD or lobar CMB and age-matched healthy controls (eg. patient's spouse or unrelated friends without SVD)\n\nExclusion Criteria:\n\n* Age\\\u003C18yo\n* Pregnant\n* Breast feeding\n* Unable to follow commands\n* Unable to tolerate MRI",true,"ALL","18 Years",{"count":63,"type":64},100,"ESTIMATED","INTERVENTIONAL",[67,68],"PHASE1","PHASE2","Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.",[71,72,73,74],"Cerebral Small Vessel Diseases","Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy","Cerebral Microbleeding","Sporadic White Matter Disease","2025-07-21",{"date":77,"type":78},"2025-07-23","ACTUAL",{"date":80,"type":78},"2021-02-09",{"date":82,"type":64},"2026-06",{"name":5,"class":6},1]